Medical device value: Here’s how you work it into your design

Public and private payers are increasingly demanding that health providers manage their patient populations more effectively and efficiently. That means that medtech companies can no longer merely rely on the strength of their technology to achieve reimbursement.

They need to demonstrate “value,” too.

“There’s a lot going on with the healthcare payment delivery systems to reform healthcare, and that’s primarily quality and cost,” said Tom Hughes, senior principal advisor at the Regulatory and Clinical Research Institute outside Minneapolis. (Meet with RCRI officials at booth #302 at DeviceTalks Boston on Oct. 2.)

But was does value mean? Value means outcomes per dollar spent – or better care through less costs, according to Hughes.

Two categories of value based evidence include clinical effectiveness – outcomes-based data – and cost effectiveness – delving into what the health providers are billing payers for their products and services.

Find out more from Hughes in our latest MDO podcast:

(Meet with RCRI officials at booth #302 at DeviceTalks Boston on Oct. 2.)

 

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW